v3 Template
T

Tevogen Bio

Biotechnology / Immunotherapy San Francisco, CA ~540 employees
Founded
--
Employees (Est.)
~540
27 leaders known
Total Funding
$290.0M
Funding Rounds
14
Last Funding
2025-08-19

About Tevogen Bio

Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision T cell therapies using its ExacTcell technology platform. The company aims to address unmet needs in large patient populations by treating infectious diseases, cancers, and other disorders, with a mission to provide affordable and accessible personalized therapies to all, regardless of socioeconomic status.

Products & Services

ExacTcell Technology:A platform harnessing CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for infectious diseases, cancers, and other disorders.
Pipeline Therapies:Investigational therapies targeting oncology, neurology, and virology, including treatments for COVID-19 and Long COVID.
PredictCell:A precision AI tool being developed with Databricks to accelerate target prediction for product development.
Tevogen Generics:An initiative to support pharmaceutical manufacturing in the United States, aligning with efforts to encourage local production.

Specialties

Precision T Cell Therapies Immunotherapy Oncology Neurology Virology Artificial Intelligence in Biotech (Tevogen.AI)

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Line of Credit and Private Placement
T: -
FT: Line of Credit and Private Placement 		A: 50000000
MR: -
FA: Up to $50 million
FAN: 50000000 		D: 2025-08-19
FD: 2025-08-19 		-
2 RT: Non-dilutive Grant
T: -
FT: Non-dilutive Grant 		A: 1000000
MR: -
FA: $1 million
FAN: 1000000 		D: 2025-08-07
FD: 2025-08-07 		1 investors
3 RT: Grant
T: -
FT: Grant 		A: 1000000
MR: -
FA: $1 million
FAN: 1000000 		D: 2025-08-01
FD: 2025-08-01 		1 investors
4 RT: Commitment
T: -
FT: Commitment 		A: 50000000
MR: -
FA: up to $50 million
FAN: 50000000 		D: 2025-04-30
FD: 2025-04-30 		1 investors
5 RT: Non-Dilutive Grant
T: -
FT: Non-Dilutive Grant 		A: 8000000
MR: -
FA: $8 million
FAN: 8000000 		D: 2025-03-03
FD: 2025-03-03 		1 investors
6 RT: Grant
T: -
FT: Grant 		A: 8000000
MR: -
FA: $8 million
FAN: 8000000 		D: 2025-03-03
FD: 2025-03-03 		1 investors
7 RT: Series C Preferred Stock
T: -
FT: Series C Preferred Stock 		A: 6000000
MR: -
FA: $6 million
FAN: 6000000 		D: 2025-02-14
FD: 2025-02-14 		-
8 RT: Grant
T: -
FT: Grant 		A: 10000000
MR: -
FA: Up to $10 million
FAN: 10000000 		D: 2025-01-28
FD: 2025-01-28 		1 investors
9 RT: Debt
T: -
FT: Debt 		A: 36000000
MR: -
FA: $36 million
FAN: 36000000 		D: 2024-11-08
FD: 2024-11-08 		-
10 RT: Series C Preferred Stock
T: -
FT: Series C Preferred Stock 		A: 6000000
MR: -
FA: 6.0 million
FAN: 6000000 		D: 2024-08-22
FD: 2024-08-22 		1 investors
11 RT: Line of Credit and Private Placement
T: -
FT: Line of Credit and Private Placement 		A: 50000000
MR: -
FA: Up to 50 million
FAN: 50000000 		D: 2024-06-11
FD: 2024-06-11 		-
12 RT: Debt and Equity Financing
T: -
FT: Debt and Equity Financing 		A: 50000000
MR: -
FA: up to $50 million
FAN: 50000000 		D: 2024-05-10
FD: 2024-05-10 		1 investors
13 RT: Series A-1
T: -
FT: Series A-1 		A: 6000000
MR: -
FA: $6.0 million
FAN: 6000000 		D: 2024-03-27
FD: 2024-03-27 		1 investors
14 RT: Series A Preferred Stock
T: -
FT: Series A Preferred Stock 		A: 8000000
MR: -
FA: $8.0 million
FAN: 8000000 		D: 2024-02-14
FD: 2024-02-14 		1 investors
Line of Credit and Private Placement Latest
2025-08-19
$50.0M
Non-dilutive Grant 2025-08-07
$1.0M
Grant 2025-08-01
$1.0M

View 13 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

R

Ryan Saadi, MD, MPH

Chairman and Chief Executive Officer

LinkedIn (Pro only)
C

Curtis Patton, PhD

Professor Emeritus of Epidemiology, Yale SPH

LinkedIn (Pro only)
S

Susan Podlogar

Former Chief HR Officer, MetLife; Independent Board Member, Tevogen Bio

LinkedIn (Pro only)
J

Jeffrey Feike, MPH

Former Hospital President, Covenant Health; Member, Board of Directors

L

Lindee Goh, PhD

Partner, Tapestry Networks; Member, Board of Directors

V

Victor J. Sordillo PE, CSP, MBA

Managing Director of Risk Advisory Services at Verita CSG

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

Tevogen Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Immunotherapy
Company Size
~540 employees (est.)
Locations
San Francisco, CA
WARREN, N.J.
WARREN, N.J., USA +6 more

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro